MDT - Medtronic's PulseSelect PFA System Gets FDA Nod Revolutionizing Atrial Fibrillation Treatment in US | Benzinga
The FDA approved Medtronic plc's (NYSE: MDT) PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF), an irregular and often very rapid heart rhythm.
PulseSelect is the first PFA technology approved for use in the U.S. and the first PFA technology with FDA breakthrough designation to win approval following the recent European CE Mark of the PulseSelect PFA system in November.
Last Month, the ...